Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Tsukasa Ikeura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0241-2821; OpenAlex author ID A5062131726, A5137973319. Sources: OpenAlex.

Their work

Papers
23 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 5 papers · 2024: 1 paper · 2025: 1 paper · 2026: 6 papers

Papers 23

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. First author DOI 10.1007/s00535-026-02432-2↗
  3. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1016/j.gastha.2025.100779↗
  4. Distinct difference of pancreatic tissue-specific microbiome in autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-44821-w↗
  5. Multi-hole Versus Fully Covered Self-expandable Metal Stents for Distal Biliary Obstruction in Unresectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002722↗
  6. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Co-author DOI 10.1111/den.70229↗
  7. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-024-16361-y↗
  8. Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal … First author DOI 10.1016/j.pan.2024.06.001↗
  9. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  10. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  11. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  12. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Co-author DOI 10.21037/jgo-23-655↗
  13. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  14. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1026↗
  15. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  16. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  17. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Co-author DOI 10.1016/j.pan.2021.03.007↗
  18. Usefulness of half-covered metallic stent placement in preventing acute cholecystitis complication in pancreatic cancer-induced distal biliary stricture. Co-author DOI 10.1002/jgh3.12409↗
  19. Effectiveness of Photodynamic Screening Using 5-Aminolevulinic Acid for the Diagnosis of Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14347↗
  20. Diffuse Pancreatic Cancer Mimicking Autoimmune Pancreatitis. Co-author DOI 10.2169/internalmedicine.2689-19↗
  21. Gastric wall abscess formation after endoscopic ultrasound-guided fine-needle aspiration of pancreatic cancer. First author DOI 10.1111/den.12571↗
  22. Relationship between autoimmune pancreatitis and pancreatic cancer: a single-center experience. Co-author DOI 10.1016/j.pan.2014.04.029↗
  23. The similarity of Type 1 autoimmune pancreatitis to pancreatic ductal adenocarcinoma with significant IgG4-positive plasma cell infiltration. Co-author DOI 10.1007/s00535-012-0677-x↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 13 shared papers, 2013–2026 · strength 2.22
  2. Daisuke Hashimoto · 12 shared papers, 2022–2026 · strength 2.19
  3. So Yamaki · 10 shared papers, 2022–2026 · strength 1.72
  4. Koh Nakamaru · 8 shared papers, 2020–2026 · strength 1.49
  5. Takashi Ito · 8 shared papers, 2019–2026 · strength 1.37
  6. Makoto Naganuma · 7 shared papers, 2020–2026 · strength 1.36
  7. Mitsugu Sekimoto · 7 shared papers, 2022–2025 · strength 1.18
  8. Tomohisa Yamamoto · 7 shared papers, 2022–2023 · strength 1.10
  9. Yuki Matsui · 5 shared papers, 2022–2025 · strength 0.89
  10. Masashi Kanai · 3 shared papers, 2025–2026 · strength 0.74
  11. Makoto Takaoka · 7 shared papers, 2013–2024 · strength 0.62
  12. Hidetaka Miyazaki · 3 shared papers, 2024–2026 · strength 0.62
  13. Kazuichi Okazaki · 7 shared papers, 2013–2022 · strength 0.57
  14. Ayaka Takaori · 3 shared papers, 2023–2026 · strength 0.54
  15. Satoshi Hirooka · 3 shared papers, 2022–2023 · strength 0.47
  16. Denys Tsybulskyi · 2 shared papers, 2023–2025 · strength 0.40
  17. Motonobu Maruo · 2 shared papers, 2024–2026 · strength 0.40
  18. Minako Nagai · 2 shared papers, 2026 · strength 0.39
  19. Ippei Matsumoto · 2 shared papers, 2026 · strength 0.39
  20. Hideaki Miyoshi · 5 shared papers, 2013–2020 · strength 0.36
  21. Tatsuma Sakaguchi · 2 shared papers, 2022–2023 · strength 0.32
  22. Kensuke Kubota · 2 shared papers, 2021–2022 · strength 0.21
  23. Itaru Naitoh · 2 shared papers, 2021–2022 · strength 0.21
  24. Terumi Kamisawa · 2 shared papers, 2021–2022 · strength 0.21
  25. Akiko Tsujimoto · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.